Substance / Medication

Imatinib mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Gupta Priyanka, Banothu Kiran Kumar, Haldar Partha et al. · J Pediatr Hematol Oncol · 2023
PMID: 37027248Meta-Analysis
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis.
Liakouli Vasiliki, Ciaffi Jacopo, Ursini Francesco et al. · Expert Rev Clin Immunol · 2020
PMID: 32893688Meta-Analysis
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
Oliveira Sicília Rezende, de Azevedo Branco Luciana Gravito, Rocha Amanda Leal et al. · Clin Oral Investig · 2019
PMID: 30968242Meta-Analysis
[Meta-analysis of imatinib mesylate with or without interferon for chronic-phase chronic myeloid leukemia].
Li Meng-qi, Zhang Ming, Liao Ai-jun et al. · Zhonghua Xue Ye Xue Za Zhi · 2013
PMID: 23978020Meta-Analysis
In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Agis H, Jaeger E, Doninger B et al. · Eur J Clin Invest · 2006
PMID: 16684124RCT
Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
Stroszczynski Christian, Jost Dominik, Reichardt Peter et al. · Eur Radiol · 2005
PMID: 16132930RCT
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira Amanda Pifano Soares, Seguro Fernanda Salles, Abdo Andre Ramires Neder et al. · Ann Hematol · 2023
PMID: 37052662ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Imatinib mesilate (substance)
SNOMED CT
129558005
UMLS CUI
C0939537

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.